NASDAQ: XCUR · Life Sciences · 2 alerts · CIK 1698530
Share price
$1.07Close, Nov 16
Market cap
$6.82M
Shares outstanding
6.37MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Exicure, Inc. filings on SEC EDGAR ↗
Exicure, Inc. and its subsidiary GPCR USA entered into a definitive agreement to sell their GPC-100 (burixafor) program assets to South Korea-based GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion) in cash. The divestiture includes intellectual property, clinical data, and the assignment of a 2025 license agreement, with the buyer assuming future milestone and royalty obligations. The sale is part of Exicure's ongoing evaluation of strategic alternatives to maximize stockholder value and strengthen its financial position.
Exicure, Inc. received an extension from Nasdaq until December 2, 2026, to regain compliance with the minimum $2.5 million stockholders' equity requirement. The company originally received a deficiency notice on June 5, 2026, and must now complete compliance initiatives to avoid potential delisting. This extension provides the company additional time to strengthen its financial position and meet continued listing standards.